Author Index for Volume 19

A

Alexander, M., 165
Arnaut, D. E., 211

B

Bahruth, A. J., 32
Baldwin, P. D., 16
Baranowski, L., 169
Barker, V. L., 182
Berrios, E., 147
Blickensderfer, L., 127
Blough, L. D., 198
Bovill, E. G., 147
Brown, J. M., 303
Burke, P. B., 117
Byrd, J. G., 117

C

Califf, R. M. 147
Campbell, K., 35
Cowan, M., 46
Crow, S., 175
Cuthreli, P., 264

D

DeAngelo, E., 141

E

Ek, A.-C., 229

G

Goetz, A. M., 103
Goldwater, R. S., 83
Granger, C. B., 147
Green, C., 147
Gruber, A., 147
Guzelaydin, S. K., 211

H

Harrington, R. A., 147
Hasler, R. A., S5
Herbert, J. R., 99
Hern, B., 269
Hinson, E. K., 198
Hogan, D. K., 256
Holk, D., 211
Hunt, M. L., Jr., S9

K

Kamitomo, V., 75
Kennedy, D., 295
Kingma, W., 79
Krucoff, M. W., 147

L

Lacy, D. E., 28
Lau, C. E., 240
Lee, W. F., III, 194
Lombardo, F., 315
Lowe-Phelps, K., 38
Lundgren, A., 229

M

McCardell, J., 211
McKee, J. M., 132
McMillan, S. C., 321
Merril, G. L., 182
Millam, D., 5
Miller, J. M., 103, 147
Moeser, L., 211
Muder, R. R., 103

O

Ohman, E. M., 147
Olson, K., 75

P

Papke, L., 211
Phillips, S., 289

R

Rapp, R. P., S9
Raulinaitis, A., 117
Reed, T., 289
Rutz, G., 28
Ryan, K. A., 123

S

Saladow, J., S20
Shotkin, J. D., 315
Spencer, D. A., 28
Squier, C., 103
St. Marie, B., 247

T

Tice, A. D., 188
Tracy, R. P., 147

V

Vallino, L. M., 194
Venkataraman, M., 28

W

Wahren, L. K., 229
Weinstein, S. M., S4, S16, S25
Weller, P. H., 28
Welsh, D., 117
Whitson, M., 251
Wilson, J. M., 307
Woodard, W. L., III, 256
Wright, A., 89

Y

Yucha, C. B., 141

Subject Index for Volume 19

A

Acute coronary syndromes, IV heparin cessation in, rebound increase in thrombin generation and activity after, 147
Alternate site infusion, physician-directed office-based model for, 188
Amphotericin B, infusion with 20% lipid emulsion, 123
Analgesia
  chemical abuse and, 247
Anesthesia, topical, PICC insertion problems and, 32
Antibiotics, in cystic fibrosis, Hydrocath vs. Vygon EC midline catheters for, 28
Antineoplastic agents. *See* Chemotherapy
Apheresis, therapeutic, for leukemia, 269

B

Bacteremia, nosocomial IV device–related, reduction of, IV therapy team and, 103

Biohazards, safety products for, 69
Blood-borne pathogens, safety products for, 69
Breast cancer, vinorelbine tartrate for, 16

C

Cancer
  chemotherapy for. *See* Chemotherapy
  emergencies in, 256
  genetically linked, prevention, diagnosis and treatment of, 321
  leukemia
    therapeutic leukapheresis in, 269
Catheters
  indwelling peripheral
    for 3–5 day outpatient chemotherapy administration, 315
Central catheters
  peripherally inserted
    in chemotherapy, normal saline lock for, 75
    gauze vs. transparent dressings for, infection rate and, 240
    open-ended vs. closed ended, 198
  venous, occlusion and repair of, 289
Chemical abuse, pain management and, 247
Chemotherapy
  administration of, 72
  emergencies in, 256
  peripheral IV catheters for, normal saline lock for, 75
  3–5 day outpatient administration of, indwelling peripheral catheter for, 315
  vinorelbine tartrate for, 16
Children, medication errors in, prevention of, 295
Continuum of care, human factors design and, S20
Cystic fibrosis, Hydrocath vs. Vygon EC midline catheters for, 28

D

Dressings, transparent vs. gauze, infection rate and, 240
Drug abuse, pain management and, 247

E

Education
  nursing
    virtual reality in, 182
Elderly, IV therapy in, 251
Employees, HIV prevention for, 69, 132
Enzyme replacement therapy, for Gaucher disease, Patient Assistance Program for, 83
Equipment failures, management of, 289, 264
Extravasation, prevention of, 89

G

Gaucher disease
  clinical characteristics and therapy for, 79
  enzyme replacement therapy for, Patient Assistance Program for, 83

H

Healthcare workers, HIV prevention for, 69, 132
Heparin, cessation of, rebound increase in thrombin generation and activity after, in acute coronary syndromes, 147
Home infusion therapy
  managing change in, 38
  Medicare for, vancomycin resistance and, 99
Human factors design, S5
  continuum of care and, S20
  in medication delivery, S25
Human immunodeficiency virus infection, healthcare worker safety issues for, 69, 132
Hydrocath midline catheter, vs. Vygon EC catheter, in cystic fibrosis, 28
Hyperemesis gravidarum, 46

I

Implanted port device, polymer, evaluation of, 303
Indwelling peripheral catheter
  for 3–5 day outpatient chemotherapy administration, 315
  mimumum discard volume for, for hematocrit analysis, 141
Infections
  intravascular, prevention of, 175
  nosocomial IV device–related
    reduction of with IV therapy team, 103
  with transparent vs. gauze dressings, 240
Infusion failure, reduction of, 89
Insertion site anesthesia, PICC insertion problems and, 32
Insertion site protectors, moisture accumulation in, 194
Intravascular infection, prevention of, 175
Intravenous Nurses Society, PICC Council, growth and development of, 211
Intravenous nursing services, marketing and promotion of, 35
Intravenous safety devices, for HIV prevention, 69, 132
Intravenous therapy
  history of, 5
  in older adults, 251
Intravenous therapy team, reduction in nosocomial IV device–related bacteremia and, 103
IVAC Signature Edition infusion pump, S25

L

Leukapheresis, therapeutic, for leukemia, 269
Leukemia, therapeutic leukapheresis in, 269
Lung cancer, non–small cell, vinorelbine tartrate for, 16

M

Managed care, human factors design and, S20
Marketing, of intravenous nursing services, 35
Medical equipment failures, management of, 289, 264
Medicare, for home infusion therapy, vancomycin resistance and, 99
Medication errors
  legal implications of, S16
  prevention of, S4 (editorial), S9
  risk management for, S16
  types of, S9
Medication errors, in children, prevention of, 295
Minimum discard volume, quantification of, 141

N

Needlestick injuries, prevention of, 69, 132
Normal saline lock, for peripheral IV catheters, in cancer patients, 75
Nosocomial IV device–related bacteremia, reduction of, IV therapy team and, 103
Nurses
  HIV prevention for, 69, 132
  physicians and, collaborative environment for, 127

Nursing education, virtual reality in, 182
Nutritional assessment, 307

O

Occupational exposures, safety products for, 69, 132
Oncologic emergencies, 256
Orthoclone OKT3, IV infusion protocol for, interdisciplinary development of, 117

P

Pain management, chemical abuse and, 247
Pediatric medication errors, prevention of, 295
Peripheral catheter
indwelling
for 3–5 day outpatient chemotherapy administration, 315
mimumum discard volume for, for hematocrit analysis, 141
Peripheral hematocrit, minimum discard volume for, quantification of, 141
Peripheral IV lines, time in situ of, complication rate and, 229
Peripherally inserted central catheters (PICC)
in chemotherapy, normal saline lock for, 75
gauze vs. transparent dressings for, infection rate and, 240
insertion problems with, topical anesthesia and, 32
open vs. closed-ended, 198
Phlebitis, prevention of, 89
Physician-directed office-based model, for alternate site infusion, 188
Physicians
HIV prevention for, 69, 132
Physicians, nurses and, collaborative environment for, 127
PICC. *See* Peripherally inserted central catheter (PICC)
PICC Council, growth and development of, 211
Polymer implanted port device, evaluation of, 303
Pregnancy, hyperemesis gravidarum in, 46
Presidential Address, 165
Presidential Report, 169
Promotion, of intravenous nursing services, 35

R

Risk management, for medication errors, S16

S

Safe Medical Devices Act, 264
Safety devices
development, selection and use of, 69
Safety devices, for HIV prevention, 69, 132
Saline lock, for peripheral IV catheters, in cancer patients, 75
Substance abuse, pain management and, 247

T

Teaching laboratory, virtual reality in, 182
Thrombophlebitis
time in situ of peripheral intravenous lines and, 229
Thrombotic events, after abrupt cessation of heparin, in acute coronary syndromes, 147
Topical anesthesia, PICC insertion problems and, 32
Transparent dressings, vs. gauze dressings, infection rate and, 240

V

Vancomycin, resistance to, 99
Vinorelbine tartrate, 16
Virtual reality, in teaching laboratory, 182
Vygon midline catheter, vs. Hydrocath catheter, in cystic fibrosis, 28